Novo Nordisk is planning to invest most in its operations in Ireland, where it plans to make the Wegovy weight-loss pill for markets outside the United States. The company intends to expand its manufacturing facility in Athlone, Co Westmeath, chief executive officer Mike Doustdar told Bloomberg in an interview. The Danish drugmaker employs about 400 people in Athlone, where employees had been told that up to 75 jobs could go. The launch of the Wegovy pill in early January has been one of the most successful pharmaceutical debuts ever with more than 240,000 Americans taking it already, Mr Doustdar said. Last October the company appointed Dilek Dogan Gurluk as general manager of Novo Nordisk Ireland.

Source: Irish Independent February 12, 2026 15:31 UTC